Albert Einstein College of Medicine, Bronx, NY.
Department of Epidemiology & Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
JCO Oncol Pract. 2023 Jun;19(6):e904-e915. doi: 10.1200/OP.22.00779. Epub 2023 Mar 31.
Incremental delays in time to treatment initiation (TTI) have been shown to cause a proportional, increased independent risk of disease-specific mortality for breast cancer, colorectal cancer (CRC), head and neck cancer (HNC), non-small-cell lung cancer (NSCLC), and pancreatic cancer. Studies suggest that delays are associated with racial and socioeconomic disparities. We evaluated associations between patient factors and TTI to identify those associated with delay.
This is a retrospective cohort study at an urban community-based academic center of patients diagnosed with or referred for curative-intent treatment of breast cancer, CRC, HNC, NSCLC, and pancreatic cancer from January 2019 to December 2021. Variables of interest included Charlson Comorbidity Index (CCI) score, insurance type, language preference, and inpatient admission 30 days before diagnosis. Factors associated with TTI delay, defined as TTI ≥ 30 days, were assessed using multivariable logistic regression.
Among 2,543 patients (69% female), the mean age was 63.4 years and the median TTI was 25 days (IQR, 6-44). Within multivariable models, patients treated as outpatient and not admitted 30 days before diagnosis experienced statistically significant greater delay for CRC (odds ratio [OR], 2.82; 95% CI, 1.71 to 4.66) and NSCLC (OR, 2.11; 95% CI, 1.31 to 3.39). Higher CCI score was associated with delay for HNC (OR, 2.63; 95% CI, 1.04 to 6.66) and NSCLC (OR, 1.75; 95% CI, 1.14 to 2.71). For breast cancer, uninsured and Spanish-speaking patients (OR, 1.79; 95% CI, 1.21 to 2.67) experienced increased TTI.
Care coordination/compliance (eg, inpatient 30 days before diagnosis), clinical (eg, medical comorbidities), and socioeconomic (eg, uninsured status) predictors for delayed TTI were identified and may inform delay minimizing interventions. Our data support evidence that TTI delays are associated with demographic and socioeconomic disparities. Existing disparities are likely exacerbated by delays that disproportionately affect patients with care coordination/compliance issues, multiple comorbidities, and lower socioeconomic status.
研究表明,治疗起始时间(TTI)的延迟与乳腺癌、结直肠癌(CRC)、头颈部癌(HNC)、非小细胞肺癌(NSCLC)和胰腺癌的疾病特异性死亡率的独立风险增加成正比。研究表明,这些延迟与种族和社会经济差异有关。我们评估了患者因素与 TTI 之间的关联,以确定与延迟相关的因素。
这是一项在城市社区学术中心进行的回顾性队列研究,研究对象为 2019 年 1 月至 2021 年 12 月期间诊断为或接受乳腺癌、CRC、HNC、NSCLC 和胰腺癌根治性治疗的患者。感兴趣的变量包括 Charlson 合并症指数(CCI)评分、保险类型、语言偏好以及诊断前 30 天的住院情况。使用多变量逻辑回归评估 TTI 延迟(定义为 TTI≥30 天)的相关因素。
在 2543 名患者(69%为女性)中,平均年龄为 63.4 岁,中位 TTI 为 25 天(IQR,6-44)。在多变量模型中,门诊治疗且诊断前 30 天未住院的患者,CRC(比值比[OR],2.82;95%CI,1.71 至 4.66)和 NSCLC(OR,2.11;95%CI,1.31 至 3.39)的 TTI 延迟显著更大。CCI 评分较高与 HNC(OR,2.63;95%CI,1.04 至 6.66)和 NSCLC(OR,1.75;95%CI,1.14 至 2.71)的 TTI 延迟有关。对于乳腺癌,未参保和讲西班牙语的患者(OR,1.79;95%CI,1.21 至 2.67)的 TTI 增加。
确定了与 TTI 延迟相关的医疗协调/合规性(例如,诊断前 30 天的住院)、临床(例如,合并症)和社会经济(例如,未参保状态)预测因素,这些因素可能为减少 TTI 延迟的干预措施提供信息。我们的数据支持 TTI 延迟与人口统计学和社会经济差异相关的证据。现有的差异可能因延迟而加剧,这些延迟对存在医疗协调/合规问题、多种合并症和较低社会经济地位的患者产生不成比例的影响。